SEC Form 4 · accession 0001209191-15-033129

INCYTE CORP · INCY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Discovery Medicinal and P

Period of report

Apr 7, 2015

Accepted (ET)

Apr 8, 2015 · 4:18 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000879169

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Apr 7, 2015	M	5,000	$17.79	A	48,720	D
Common Stock^F1,F2,F3	Apr 7, 2015	S	5,000	$90.25	D	43,720	D
Common Stock^F1,F2,F3	Apr 7, 2015	S	1,853	$90.27	D	41,867	D
Common Stock^F1,F2,F4	Apr 7, 2015	S	3,178	$90.22	D	38,689	D
Common Stock^F1,F2,F3	Apr 7, 2015	S	5,000	$90.29	D	33,689	D
Common Stock^F2	Apr 7, 2015	S	5,000	$89.75	D	28,689	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F5	$17.79	Apr 7, 2015	M	5,000	D	—	Jan 18, 2019	Common Stock	5,000	58,354	D

F1Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
F2This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
F3Represents weighted average sale price. Actual sale prices ranged from $89.15- $91.00.
F4Represents weighted average sale price. Actual sale prices ranged from $89.15- $91.03.
F5Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.